A patient taking sertraline, sold under the brand name Zoloft, can screen positive for benzodiazepines on a standard urine immunoassay without ever having taken a benzodiazepine. This is not a rare fluke. It is a documented cross-reactivity issue that shows up repeatedly in the clinical literature and in the drug's own FDA label. Anyone who orders, reads, or reviews drug screens, clinics, employers, MROs, and the patients themselves, should understand why it happens, how often, and what actually resolves it.
Why sertraline shows up as a benzodiazepine on a screen
Immunoassay screening tests work by using antibodies designed to bind to a target drug or drug class. Those antibodies are built for specificity, but they are not perfect. When a compound has a molecular shape similar enough to the target, the antibody can bind it too, producing a positive signal even though the actual target drug is absent. This is cross-reactivity, and it is a known limitation of immunoassay technology generally, not a defect specific to any one manufacturer's kit. The NIH Bookshelf's overview of toxicology screening explains that immunoassays "demonstrate reduced sensitivity and specificity compared to earlier techniques" and "remain vulnerable to cross-reactivity with structurally related compounds," which is exactly the mechanism at work with sertraline and benzodiazepine assays.
The FDA-approved prescribing information for sertraline states this directly: "False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking sertraline." The label attributes this to the lack of specificity of the screening tests themselves, not to any risk associated with the drug, and it notes that a false positive may still appear for several days after a patient stops taking sertraline, since the drug and its metabolite norsertraline clear the body gradually rather than all at once.
What the research actually found
The clearest evidence comes from a two-year retrospective chart review published in Innovations in Clinical Neuroscience and archived in full at PubMed Central. Researchers reviewed 522 urine drug screens that had come back presumptively positive for benzodiazepines on an Abbott AEROSET and ARCHITECT c8000 immunoassay platform. Gas chromatography-mass spectrometry confirmation cleared 160 of those as false positives. Of the 98 false positives that were not explained by an actual benzodiazepine prescription, 26 patients, or about 26.5 percent, had an active sertraline prescription on file. The authors noted this figure was consistent with an earlier published study, which found a similar association in roughly 32 percent of unexplained false positives.
The same paper cites an update Abbott made to its benzodiazepine assay package insert in 2008, which specifically flagged sertraline and its metabolite norsertraline as capable of producing a positive signal at concentrations described as at least 200 times higher than what would be expected from normal therapeutic sertraline dosing in a typical patient. In practice this means the effect is dose-related and assay-related rather than universal, but it is well established enough that manufacturers document it in their own product inserts.
Which assay platforms are affected
The published false-positive data centers on Abbott's benzodiazepine immunoassay, run on the AEROSET and ARCHITECT c8000 chemistry systems, which are common in hospital and reference laboratories. Cross-reactivity is a property of the specific antibody reagent used in a given assay, so not every benzodiazepine immunoassay kit on the market will behave identically, and rates can vary by manufacturer, cutoff concentration, and instrument. This is exactly why a screen result should never be treated as a final answer for a compound like sertraline. It is also why a large-scale analysis of electronic health records and urine drug screen data, published through PubMed Central, found benzodiazepine assay false-positive rates that varied widely across different screening platforms, and identified separate confirmation gaps such as clobazam, an actual prescribed benzodiazepine that some screening assays detect but that a lab's specific confirmation panel may not separately identify, leading to a different kind of screen-versus-confirm mismatch.
Sertraline and the LSD panel
Benzodiazepines are not the only place sertraline interferes. A case report indexed in the National Library of Medicine's PubMed database describes a positive interference between sertraline and the CEDIA LSD immunoassay, a screening method used on some expanded panels that include lysergic acid diethylamide. The CEDIA platform is generally considered more specific than older EMIT-based LSD screening, but the report documented a cross-reaction with sertraline that had not previously been described in the literature, alongside known interferents like ambroxol and fentanyl. Programs that run LSD or hallucinogen panels should be aware that an SSRI prescription is a plausible explanation for an unexpected non-negative result there as well, and it should be handled the same way as a BZO non-negative: through confirmation, not through an assumption of drug use.
Why confirmation testing clears it
Gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry work on a fundamentally different principle than immunoassay screening. Instead of relying on antibody binding, these methods separate and identify compounds by their actual chemical structure and mass. The NIH Bookshelf describes GC-MS as remaining "the reference standard for confirmatory testing," with LC-MS increasingly used alongside it in both clinical and forensic settings. Sertraline and norsertraline have distinct chemical signatures from any benzodiazepine or from LSD, so confirmation testing separates them cleanly. This is the entire reason federal and most clinical drug testing programs require a non-negative immunoassay screen to be confirmed before it is ever reported as a verified positive. A screen is a triage tool built for speed and sensitivity. A confirmation test is the diagnostic answer.
What a patient should disclose to the MRO
When a Medical Review Officer reviews a confirmed non-negative result, the process is built around exactly this kind of situation. SAMHSA's guidance manual for medical review officers describes the verification interview: the MRO informs the donor of the laboratory result and asks whether there is a possible explanation. If the donor states that a prescribed medication may have interfered with the test, the MRO can ask for supporting documentation, such as a pharmacy printout or a copy of the prescription, before making a final determination. A patient taking sertraline who receives a non-negative benzodiazepine or LSD screen should disclose the prescription immediately, be ready to provide pharmacy records or a prescriber's contact information, and let the MRO connect the dots between the medication and the assay's known cross-reactivity. This is not an unusual or suspicious request. It is the standard mechanism built into MRO review for exactly this scenario.
How clinics and employers should treat a BZO non-negative
A non-negative immunoassay screen is a presumptive result, not a diagnosis of drug use. Clinics, treatment programs, and employers should never take adverse action, whether clinical, disciplinary, or otherwise, based on a screen alone when a legitimate SSRI prescription is in play. The correct sequence is the same one used across regulated and non-regulated testing programs: reflex the non-negative to GC-MS or LC-MS confirmation, review the patient's or employee's current medication list before drawing conclusions, and route the result through a qualified reviewer, ideally an MRO or a clinician trained in interpreting toxicology results, rather than reading the screen itself as final. Programs that skip confirmation on benzodiazepine panels are the ones most exposed to sertraline-driven false positives, since the antibody cross-reactivity lives entirely at the screening stage. Building that confirmation step into a program's standard workflow, using drug testing supplies paired with a lab confirmation pathway, closes the gap before it becomes a dispute.
SSRIs and other drugs with documented benzodiazepine cross-reactivity
| Substance | Drug class | Assay affected | What the evidence shows |
|---|---|---|---|
| Sertraline (Zoloft) | SSRI antidepressant | Benzodiazepine immunoassay (Abbott AEROSET/ARCHITECT and others) | Associated with roughly 26 to 32 percent of unexplained benzodiazepine false positives in two independent chart reviews; documented on the FDA label |
| Sertraline (Zoloft) | SSRI antidepressant | CEDIA LSD immunoassay | Case report documented positive interference with the LSD screen, a previously unreported cross-reaction |
| Oxaprozin (Daypro) | NSAID | Benzodiazepine immunoassay | A published laboratory report documented false-positive benzodiazepine immunoassay results in patients on oxaprozin |
| Clobazam | Benzodiazepine (actual prescribed drug) | Benzodiazepine screen vs. confirmation panel | A real benzodiazepine that some screening assays detect but that a lab's confirmation panel may not separately resolve, creating a screen-confirm mismatch rather than a true cross-reactivity artifact |
The pattern across every row is the same. A screening immunoassay is a fast, sensitive, first-pass tool, and it is not the final word on any single specimen. This is exactly why the field distinguishes between a screen and a confirmed result on a BZO panel, and why the confirmation step exists at all.
The screen versus confirm principle
Every immunoassay drug screen, no matter how well designed, trades some specificity for speed and cost. That tradeoff is intentional and reasonable for a first-pass tool, but it means a non-negative screen result is properly described as presumptive, not positive, until it has been through confirmation. Sertraline's documented interference with benzodiazepine and LSD assays is one of the clearest illustrations of why this distinction matters in practice. A patient on a standard, appropriately dosed antidepressant can trigger a screen that looks alarming, and a program that treats the screen as final rather than routing it to GC-MS or LC-MS confirmation and MRO review risks an incorrect and avoidable outcome. Understanding how the MRO process is structured to catch exactly this kind of medication-driven false positive is part of running a defensible testing program.
Frequently asked questions
Does sertraline actually contain or metabolize into a benzodiazepine?
No. Sertraline is a selective serotonin reuptake inhibitor, chemically unrelated to benzodiazepines. The false-positive result comes from the screening antibody reacting to a structural similarity between sertraline or its metabolite norsertraline and the assay's target molecule, not from any actual benzodiazepine content.
Will a confirmation test also come back positive if someone is only taking sertraline?
No. Gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry identify compounds by their actual chemical structure rather than by antibody binding, so they correctly distinguish sertraline from any benzodiazepine and will not confirm a positive in the absence of actual benzodiazepine use.
Does the dose of sertraline matter?
The evidence suggests the interference is concentration-related. The manufacturer's assay package insert cited in the retrospective chart review describes sertraline and norsertraline producing a positive signal at concentrations well above typical therapeutic exposure, which is consistent with why not every patient on sertraline triggers a false positive.
Should a clinic stop testing patients who take sertraline for benzodiazepines?
No. The correct response is not to skip testing but to route any non-negative benzodiazepine or LSD screen result through confirmatory testing and a qualified reviewer, while documenting the patient's current medication list at intake so a false positive can be identified quickly rather than assumed to reflect drug use.
Does this affect DOT-regulated testing?
Standard DOT panels do not include a benzodiazepine or LSD test, so this specific cross-reactivity issue does not arise in federally mandated DOT collections. It applies to non-DOT, clinical, and treatment-program panels that include an expanded benzodiazepine or hallucinogen screen.
Related reading
This article is general information, not medical or legal advice. Interpretation of any non-negative drug screen result should go through a qualified Medical Review Officer or laboratory toxicologist, and confirmatory testing before any clinical or employment decision is made.
